Manachai Nawin, Umnuayyonvaree Duangchanok, Punyathi Panitnan, Rungsipipat Anudep, Rattanapinyopituk Kasem
Department of Pathology, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Center of Excellence - Companion Animal Cancer (CE-CAC), Chulalongkorn University, Pathumwan, Bangkok, Thailand.
Vet World. 2022 Dec;15(12):2810-2815. doi: 10.14202/vetworld.2022.2810-2815. Epub 2022 Dec 10.
C-reactive protein (CRP) is a highly sensitive but non-specific acute phase protein that has been widely used to predict the biological behavior of patients with cancer. This study aimed to examine the significance of the serum CRP biomarker in predicting the prognosis of dogs with lymphoma.
Blood samples (5 mL) were collected from 34 lymphoma dogs and control healthy dogs. Canine lymphoma clinical staging was classified using the World Health Organization (WHO) criteria. All lymphoma dogs were reclassified into two groups based on the disease stage. Stages IV and V were designated as advanced stages, and Stages I-III were designated as other stages. The serum CRP level was then determined using a commercial canine CRP fluorescent immunoassay kit and routine hematological and biochemical analyses. C-reactive protein levels, circulating inflammatory parameters, such as neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, and albumin levels were compared between advanced stages (IV and V) and Stages I to III using Mann-Whitney U tests. Receiver operating characteristic (ROC) curves were also generated to determine the cutoff value, diagnostic sensitivity, and specificity of the CRP level.
A prospective study identified 34 dogs recently diagnosed with canine lymphoma. C-reactive protein levels were significantly higher in lymphoma dogs in advanced stages (IV and V) than in lymphoma dogs in Stages I-III. According to the ROC curve analysis, a CRP cutoff level of 54.1 mg/L indicates advanced-stage canine lymphoma, which can be used as a biomarker to predict cancer dissemination.
Serum CRP concentrations can assist clinical decision-making on the WHO stage in lymphoma dogs in clinical applications. The limitations of this study include a small number of lymphomas and no survival analysis.
C反应蛋白（CRP）是一种高度敏感但非特异性的急性期蛋白，已被广泛用于预测癌症患者的生物学行为。本研究旨在探讨血清CRP生物标志物在预测犬淋巴瘤预后中的意义。
采集34只淋巴瘤犬和对照健康犬的血样（5毫升）。采用世界卫生组织（WHO）标准对犬淋巴瘤进行临床分期。所有淋巴瘤犬根据疾病分期重新分为两组。IV期和V期被指定为晚期，I - III期被指定为其他阶段。然后使用商用犬CRP荧光免疫分析试剂盒以及常规血液学和生化分析来测定血清CRP水平。使用Mann - Whitney U检验比较晚期（IV期和V期）与I至III期之间的C反应蛋白水平、循环炎症参数，如中性粒细胞与淋巴细胞比率、淋巴细胞与单核细胞比率以及血小板与淋巴细胞比率，以及白蛋白水平。还生成了受试者操作特征（ROC）曲线以确定CRP水平的临界值、诊断敏感性和特异性。
一项前瞻性研究确定了34只最近被诊断患有犬淋巴瘤的犬。晚期（IV期和V期）淋巴瘤犬的C反应蛋白水平显著高于I - III期淋巴瘤犬。根据ROC曲线分析，CRP临界值水平为54.1毫克/升表明为晚期犬淋巴瘤，可作为预测癌症扩散的生物标志物。
血清CRP浓度可在临床应用中辅助对淋巴瘤犬进行WHO分期的临床决策。本研究的局限性包括淋巴瘤病例数量少且未进行生存分析。
